Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 832,200 shares, a decline of 31.2% from the September 15th total of 1,210,000 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average trading volume of 521,200 shares, the days-to-cover ratio is currently 1.6 days.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Cara Therapeutics in a research note on Saturday. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $2.32.
View Our Latest Research Report on CARA
Institutional Investors Weigh In On Cara Therapeutics
Cara Therapeutics Stock Performance
Shares of NASDAQ CARA remained flat at $0.25 during midday trading on Friday. The stock had a trading volume of 356,264 shares, compared to its average volume of 639,855. The company has a market capitalization of $13.70 million, a P/E ratio of -0.11 and a beta of 0.70. Cara Therapeutics has a 52-week low of $0.24 and a 52-week high of $1.65. The company’s 50 day moving average is $0.31 and its 200 day moving average is $0.48.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The firm had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. Research analysts predict that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Read More
- Five stocks we like better than Cara Therapeutics
- What is the S&P/TSX Index?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- How to Most Effectively Use the MarketBeat Earnings Screener
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Breakout Stocks: What They Are and How to Identify Them
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.